Free Trial

Cartesian Therapeutics (RNAC) News Today

→ Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad)
Free RNAC Stock Alerts
$36.58
+1.88 (+5.42%)
(As of 06/7/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends
June 9 at 2:24 AM | americanbankingnews.com
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Rating of "Buy" from Analysts
June 6 at 7:05 AM | globenewswire.com
Cartesian Therapeutics Announces New Employment Inducement Grant
June 5, 2024 | americanbankingnews.com
Cartesian Therapeutics (NASDAQ:RNAC) Receives New Coverage from Analysts at Oppenheimer
June 4, 2024 | marketbeat.com
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Average Rating of "Buy" from Analysts
Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) have been given an average rating of "Buy" by the six brokerages that are presently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price targ
June 4, 2024 | marketbeat.com
Cartesian Therapeutics (NASDAQ:RNAC) Coverage Initiated by Analysts at Oppenheimer
Oppenheimer began coverage on Cartesian Therapeutics in a research note on Tuesday. They issued an "outperform" rating and a $50.00 target price on the stock.
June 3, 2024 | marketbeat.com
Cartesian Therapeutics (NASDAQ:RNAC) Trading 7.7% Higher
Cartesian Therapeutics (NASDAQ:RNAC) Shares Up 7.7%
June 2, 2024 | americanbankingnews.com
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Short Interest Update
June 2, 2024 | marketbeat.com
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Sees Large Growth in Short Interest
Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) was the target of a large growth in short interest in May. As of May 15th, there was short interest totalling 948,400 shares, a growth of 20.9% from the April 30th total of 784,200 shares. Based on an average daily volume of 73,000 shares, the days-to-cover ratio is currently 13.0 days. Currently, 13.7% of the shares of the stock are short sold.
May 24, 2024 | msn.com
Mizuho Initiates Coverage of Cartesian Therapeutics (RNAC) with Buy Recommendation
May 24, 2024 | markets.businessinsider.com
Buy Rating Affirmed for Cartesian Therapeutics Amidst Promising Clinical Advancements and Strategic Positioning
May 24, 2024 | msn.com
Mizuho starts Cartesian at buy, cites lead drug asset
May 24, 2024 | marketbeat.com
Cartesian Therapeutics (NASDAQ:RNAC) Now Covered by Mizuho
Mizuho began coverage on shares of Cartesian Therapeutics in a report on Friday. They set a "buy" rating and a $40.00 target price on the stock.
May 23, 2024 | marketbeat.com
HC Wainwright Reiterates "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC)
HC Wainwright reiterated a "buy" rating and set a $54.00 price objective on shares of Cartesian Therapeutics in a report on Thursday.
May 22, 2024 | msn.com
Cartesian stock climbs 8% on FDA regenerative therapy designation
May 22, 2024 | markets.businessinsider.com
Cartesian: FDA Grants Regenerative Medicine Advanced Therapy Designation For Descartes-08
May 22, 2024 | globenewswire.com
Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis
May 17, 2024 | edition.cnn.com
Cartesian Therapeutics, Inc.
May 13, 2024 | globenewswire.com
Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 13, 2024 | benzinga.com
What Makes Cartesian Therapeutics, Inc. a New Buy Stock
May 10, 2024 | markets.businessinsider.com
Buy Rating Affirmed for Cartesian Therapeutics on Strong Clinical Progress and Strategic Expansion
May 10, 2024 | finance.yahoo.com
Cartesian Therapeutics Inc (RNAC) Reports Q1 2024 Earnings: A Detailed Financial and ...
May 10, 2024 | marketbeat.com
Cartesian Therapeutics, Inc. to Post FY2028 Earnings of ($7.41) Per Share, Leerink Partnrs Forecasts (NASDAQ:RNAC)
Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Stock analysts at Leerink Partnrs issued their FY2028 earnings per share (EPS) estimates for Cartesian Therapeutics in a research report issued on Wednesday, May 8th. Leerink Partnrs analyst T. Smith forecasts that the company will earn (
May 10, 2024 | markets.businessinsider.com
Buy Rating Affirmed on Cartesian Therapeutics with Promising Descartes-08 Therapy Outlook and Strong Financials
May 9, 2024 | marketbeat.com
Cartesian Therapeutics (NASDAQ:RNAC) Stock Rating Reaffirmed by HC Wainwright
HC Wainwright restated a "buy" rating and set a $54.00 price objective on shares of Cartesian Therapeutics in a research note on Thursday.
May 9, 2024 | finance.yahoo.com
Cartesian Therapeutics Reports First Quarter 2024 Earnings
May 8, 2024 | msn.com
Cartesian Therapeutics GAAP EPS of -$10.50, revenue of $5.84M
May 8, 2024 | investorplace.com
RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q1 2024
May 8, 2024 | marketbeat.com
Cartesian Therapeutics (NASDAQ:RNAC) Given "Buy" Rating at Needham & Company LLC
Needham & Company LLC reiterated a "buy" rating and issued a $42.00 price objective on shares of Cartesian Therapeutics in a research report on Wednesday.
May 8, 2024 | finanznachrichten.de
Cartesian Therapeutics, Inc.: Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 8, 2024 | globenewswire.com
Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 6, 2024 | businesswire.com
Cartesian Therapeutics Announces New Employment Inducement Grants
April 25, 2024 | marketbeat.com
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) to Post Q1 2024 Earnings of ($0.27) Per Share, HC Wainwright Forecasts
Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Investment analysts at HC Wainwright upped their Q1 2024 earnings per share estimates for Cartesian Therapeutics in a note issued to investors on Tuesday, April 23rd. HC Wainwright analyst M. Kapoor now anticipates that the company will p
April 24, 2024 | marketbeat.com
FY2027 Earnings Forecast for Cartesian Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:RNAC)
Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Stock analysts at Leerink Partnrs issued their FY2027 earnings per share (EPS) estimates for shares of Cartesian Therapeutics in a research report issued to clients and investors on Tuesday, April 23rd. Leerink Partnrs analyst T. Smith fo
April 24, 2024 | marketbeat.com
Leerink Partnrs Reiterates Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC)
Leerink Partnrs reaffirmed an "outperform" rating on shares of Cartesian Therapeutics in a report on Tuesday.
April 23, 2024 | markets.businessinsider.com
Buy Rating Affirmed for Cartesian Therapeutics: Promising CAR-T Therapy and Strategic Financial Moves
April 23, 2024 | marketbeat.com
Cartesian Therapeutics (NASDAQ:RNAC) Price Target Raised to $54.00 at HC Wainwright
HC Wainwright increased their price target on Cartesian Therapeutics from $2.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday.
April 22, 2024 | businesswire.com
Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting
April 15, 2024 | msn.com
Marinus Pharmaceuticals, Cartesian Therapeutics, Adial Pharmaceuticals among healthcare movers
April 5, 2024 | marketbeat.com
Cartesian Therapeutics (NASDAQ:RNAC) Sets New 1-Year Low at $13.19
Cartesian Therapeutics (NASDAQ:RNAC) Reaches New 1-Year Low at $13.19
April 5, 2024 | marketbeat.com
Trading was temporarily halted for "RNAC" at 07:04 PM with a stated reason of "News pending."
April 4, 2024 | businesswire.com
Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 4, 2024 | businesswire.com
Cartesian Therapeutics Announces New Employment Inducement Grants
April 1, 2024 | marketbeat.com
Short Interest in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Expands By 27.3%
Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) was the recipient of a large growth in short interest in March. As of March 15th, there was short interest totalling 8,300,000 shares, a growth of 27.3% from the February 29th total of 6,520,000 shares. Based on an average trading volume of 692,200 shares, the short-interest ratio is presently 12.0 days. Currently, 7.8% of the company's stock are sold short.
March 28, 2024 | globenewswire.com
Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split
March 21, 2024 | insidertrades.com
Insider Buying: Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Director Buys 19,044 Shares of Stock
March 21, 2024 | finance.yahoo.com
Cartesian Therapeutics Director Acquires 3.2% More Stock
March 20, 2024 | marketbeat.com
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Director Buys $11,426.40 in Stock
Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) Director Timothy A. Springer acquired 19,044 shares of the company's stock in a transaction on Monday, March 18th. The stock was bought at an average price of $0.60 per share, for a total transaction of $11,426.40. Following the purchase, the director now owns 31,073,406 shares in the company, valued at approximately $18,644,043.60. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
March 19, 2024 | insidertrades.com
Timothy A. Springer Purchases 648,372 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Stock
March 18, 2024 | markets.businessinsider.com
Buy Rating Affirmed for Cartesian Therapeutics: Neutral Impact of Xork Termination and High Hopes for Descartes-08 Trial
March 18, 2024 | marketbeat.com
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Director Timothy A. Springer Purchases 648,372 Shares
Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) Director Timothy A. Springer bought 648,372 shares of the business's stock in a transaction on Thursday, March 14th. The shares were acquired at an average cost of $0.54 per share, for a total transaction of $350,120.88. Following the purchase, the director now directly owns 30,516,862 shares in the company, valued at $16,479,105.48. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Get Cartesian Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter.

Urgent alert: open this for a huge profit potential (Ad)

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

See Tim’s instructions to make this remarkably simple trade right here

RNAC Media Mentions By Week

RNAC Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RNAC
News Sentiment
▼
0.85

0.75
▲
Average
Medical
News Sentiment

RNAC News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RNAC Articles
This Week
▼
8

2
▲
RNAC Articles
Average Week

Get Cartesian Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:RNAC) was last updated on 6/9/2024 by MarketBeat.com Staff

From Our Partners
Breaking - The US Gov. Seized CITGO
Do you want an investment that can double or triple your money in the next three months? The US Court is cu...
Augury Research | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored
AI's Next Magnificent Seven
The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.
The Oxford Club | Sponsored
Write this ticker symbol down…
A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...
StocksToTrade | Sponsored
Urgent alert: open this for a huge profit potential
This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo...
Timothy Sykes | Sponsored
Are You Positioned For The New Energy Goldrush?
Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...
Wealthpin Pro | Sponsored